Study # | Author | Publication year | Region | Sample size | Good Adherence Definition | Disclosure Outcomes | Good adherence | OR | |
---|---|---|---|---|---|---|---|---|---|
Among disclose | Among non-disclose | Â | |||||||
1 | Mitiku et al. [37] | 2013 | Harari | 239 | > 95% of prescribed ARV drugs for the past 7 days. | Family or others | 164/208 | 44/208 | 1.09 |
2 | Mohammed et al. [38] | 2015 | Oromia | 237 | <  3 missed doses/day over study period | Community | 175/197 | 22/197 | 3.41 |
3 | Ketema et al. [36] | 2015 | Amhara | 422 | 0 missed dose during the 30-day period prior to filling out the self-report. | Religious leaders and others | 357/422 | 65/422 | 1.96 |
4 | Alagaw et al. [33] | 2013 | SNNPR | 357 | > = 95% of prescribed drugs in past 7 days. | No specifics regarding disclosure | 281/312 | 31/312 | 2.59 |
5 | Tsega et al. [18] | 2015 | Amhara | 351 | <  3 missed doses over the entire time of therapy (Range: >6mo to < 3 yr) | Family | 265/284 | 19/284 | 1.13 |
6 | Gelan [35] | 2010 | SNNPR | 277 | Patients who reported an intake of 95% or more of the prescribed medication | Partner, family, relatives, friends and community | 86/182 | 96/182 | 1.85 |
7 | Asmare et al. [34] | 2014 | Amhara | 377 | <  3 missed doses per month | Family/Relatives | 37/55 | 18/55 | 0.85 |